ClinicalTrials.gg
CompletedNCT00292266Updated Aug 5, 2013

A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS)

A Phase 3 interventional study of Rebif® and Avonex® in Multiple Sclerosis, Relapsing-Remitting, sponsored by EMD Serono. Completed. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2013-08-05.

Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
677
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, none under way, none of them phase 3. Interferon beta-1a · Multiple Sclerosis, Relapsing-Remitting.

Enrollment
3rd of 21
677 · median 80
Started
1999
with 1 other
Phase 3
3 of 21
none open now
Registered
6th of 21
by date
Lead sponsor
3 of 21
EMD Serono

Among the 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting, this one is the 3rd largest by enrollment, is one of 2 that started in 1999, is one of 3 in phase 3, and was the 6th registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

None of the 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →

About Interferon beta-1a

Interferon beta-1a: first FDA approval 1996 (AVONEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting as a file.
02

Study summary

This is an open-label, randomized, multicenter, comparative, and parallel-group study comparing the therapeutic effects of two interferon-beta-1a regimens in relapsing-remitting multiple sclerosis (MS). The primary objective is to demonstrate the superiority of Rebif® 44 microgram (mcg) subcutaneous injection given three times a week (132 mcg per week) to that of Avonex® 30 mcg intramuscular injection given once a week.

03

Conditions studied

  • Multiple Sclerosis, Relapsing-Remitting

Keywords

  • Relapsing-remitting Multiple Sclerosis
  • Rebif®
  • Avonex®
  • interferon-beta-1a
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 55 years
  • Clinically definite or laboratory-supported definite relapsing-remitting MS according to Poser's criteria
  • Two or more relapses within the preceding 24 months
  • Clinical stability or improving neurological state during the 4 weeks before Study Day 1
  • Expanded disability status scale (EDSS) score from 0 to 5.5, inclusive
  • Two or more lesions consistent with MS on a Screening proton density/T2-magnetic resonance imaging (MRI) scan to be performed 28 plus/minus (+/-) 4 days before the Study Day 1 MRI
  • Willingness and ability to comply with the protocol for the duration of the study
  • Written given before any study-related procedure not part of the subject's normal medical care, with the understanding that the subject can withdraw consent at any time without prejudice to future medical care
  • For female subjects, lack of must be satisfied by either being or surgically sterilized or using a hormonal , intra-uterine device, diaphragm with spermicide or condom with spermicide for the duration of the study. Subjects should neither be pregnant nor breast-feeding; confirmation that the subject is not pregnant will be established by a negative serum human chorionic gonadotropin (hCG) pregnancy test within 7 days of Study Day 1 (the pregnancy test will not be required of subjects who will be post-menopausal or surgically sterilized)

Exclusion criteria

Exclusion Criteria:

  • Secondary progressive MS, primary progressive MS or progressive relapsing MS
  • Prior use of interferon
  • Treatment with oral or systemic or adrenocorticotropic hormone (ACTH) within 4 weeks of Study Day 1 or within 7 days before the Screening MRI
  • Psychiatric disorder that is unstable or will preclude safe participation in the study
  • Significant leucopenia (white blood cell count less than 0.5 times the lower limit of normal) within 7 days of Study Day 1
  • Elevated liver function tests ( [ALT], Aspartate transaminase [AST], alkaline phosphatase or total greater than 2 times the ) within 7 days of Study Day 1
  • Prior cytokine or anti-cytokine therapy or glatiramer acetate within the 3 months before Study Day 1
  • Immunomodulatory or therapy within the 12 months before Study Day 1, including but not limited to cyclophosphamide, cyclosporin, methotrexate, azathioprine, linomide and mitoxantrone
  • Previous use of cladribine or total lymphoid irradiation
  • Allergy to human serum albumin, mannitol or gadolinium diethylenetriaminepentacetic acid (DTPA)
  • Intravenous immunoglobulin or any other drug or procedure in the 6 months before Study Day 1
  • Systemic disease that can interfere with subject safety, compliance or evaluation of the condition under study, such as insulin-dependent diabetes, Lyme disease, cardiac disease or infection with (HIV) or Human T-cell lymphotrophic virus, Type-1 (HTLV-1)
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
677 participants (actual)

Study arms

  • Experimental
    Rebif®

    Drug: Rebif®

  • Active comparator
    Avonex®

    Drug: Avonex®

Interventions

  • Rebif® injection will be administered subcutaneously at a dose of 44 mcg, three times per week, up to 72 weeks.

  • Avonex® injection will be administered intramuscularly at a dose of 30 mcg, once weekly, up to 72 weeks.

06

What researchers measure

Primary outcomes

  1. Percentage of exacerbation-free subjects

    Time frame: Week 24

  2. Percentage of exacerbation-free subjects

    Time frame: Week 48

  3. Percentage of exacerbation-free subjects

    Time frame: Week 72

Secondary outcomes

  1. Mean number of combined unique (CU) active lesions per subject per scan

    Time frame: Week 24

  2. Total exacerbation count per subject

    Time frame: Week 24, 48 and 72

  3. Mean Number of Time constant 2 (T2) active lesions per subject per scan

    Time frame: Week 24, 48 and 72

07

Study locations

No study locations are listed for this record.

08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 1999, a primary completion of Jun 2002 and a completion of Jun 2002. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2006
First posted
Feb 15, 2006
Start
Nov 1999
Primary completionActual
Jun 2002
CompletionActual
Jun 2002
Last update
Aug 5, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00292266
Lead sponsor
EMD Serono
Collaborators
Merck Serono International SA
Responsible party
Sponsor
First posted
Feb 15, 2006
Start date
Nov 1999
Primary completion
Jun 2002
Completion
Jun 2002
Last update
Aug 5, 2013

Study contacts

Gordon Francis, M.D.
study director · Merck Serono International SA
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Interferon beta-1a

Start the discussion